(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...
Imviva Biotech maintains ongoing collaboration with the FDA, as demonstrated by the February 2025 IND clearance and January 2026 orphan drug designation for CD7-targeted therapy CTD402 in T-cell ...
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ...
Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell ...
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.
The granting of RMAT designation reflects the FDA's recognition of the potential for lasme-cel to address the unmet medical need faced by patients with r/r B-ALL.
6don MSN
CAR-T therapy may also help patients with kidney failure, new Penn Medicine clinical trial finds
Researchers at Penn Medicine say the revolutionary cancer treatment CAR-T therapy may also help patients with kidney failure.
A 54-year-old woman, Sunita, has achieved complete remission from aggressive B-ALL after a challenging treatment journey ...
T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...
CAR T-cell therapy successfully cleared anti-HLA antibodies to enable kidney transplantation in three highly sensitized ...
CAR-T cell therapy, a breakthrough treatment originally for blood cancers, is now offering hope for kidney transplant in hard-to-match patients and rheumatology disorders. Recent studies show its ...
A retrospective study evaluates the effectiveness of CD19 CAR T-cell therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with extramedullary or CNS disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results